Phase I, Open-label, Single-center Proof of Concept Study Designed to Test the Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in Combination With CDX-301 in Subjects With a History of Prostate Cancer, in the Adjuvant Setting
Latest Information Update: 30 Oct 2024
At a glance
Most Recent Events
- 28 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2023 Planned End Date changed from 1 Dec 2027 to 1 Jan 2028.
- 18 Oct 2023 Planned primary completion date changed from 1 Dec 2026 to 1 Jan 2027.